Hiperaldosteronismo primario, una nueva perspectiva

Autores/as

  • Karen Gómez Hernández Caja Costarricense del Seguro Social, Hospital San Juan de Dios
  • Chih Hao Chen-Ku Caja Costarricense del Seguro Social, Hospital San Juan de Dios

DOI:

https://doi.org/10.51481/amc.v49i1.287

Palabras clave:

Hiperaldosteronismo primario, hipertensión arterial, prevalencia

Resumen

Hace cincuenta años se describió por primera vez el hiperaldosteronismo primario que hasta hace poco se consideraba un síndrome infrecuente y una causa excepcional de hipertensión arterial. De cada 10 pacientes hipertensos habrá en promedio uno de ellos con este padecimiento, convirtiendo a tal grupo de enfermedades en la causa más frecuente de hipertensión potencialmente curable. Este incremento en la prevalencia se debe quizás al aumento en la sensibilidad de las pruebas de tamizaje utilizadas. Si bien es cierto, los nuevos hallazgos no implican necesariamente el tamizaje generalizado de la población de hipertensos; es importante que el médico que la controla esté familiarizado con el tema para que lo considere y lo sospeche en el manejo y seguimiento de sus pacientes.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Williams JS, Williams GH. 50th anniversary of aldosterone. J Clin Endocrin Metab 2003; 88: 2364-2372.

Arlt W, Allolio B. Adrenal insuffi ciency. Lancet 2003; 361: 1881-93.

Løvås K, Husebye ES. Addison´s disease. Lancet 2005; 365: 205861.

Simpson SA, Tait JF, Bush IE. Secretion of a salt-retaining hormone by the mammalian adrenal cortex. Lancet 1952; 2:226-228.

Conn JW. Presidential address: 1) Painting background. 2) Primary aldosteronism, a new clinical syndrome. J. Lab. Clin. Med. 1955; 45:3-17.

McDermott MT. Endocrine secrets. 4th ed., USA: Elsevier, 2005.

Ganguly, A. Primary aldosteronism. N Engl J Med 1998; 339:182934.

Don BR, Biglieri EG, Schambelan M. Hipertensión Endocrina. En: Greenspan FS, Strewler GJ, ed. Endocrinología Básica y Clínica. 4 ed., México: El Manual Moderno, 1998:411-434.

Vallotton MB. Primary aldosteronismo. I Diagnosis of primary aldosteronism. Clin Endocrnol. 1999;45:47-52.

Young WF. Minireview: Primary aldosteronism. Endocrinology 2003; 144: 2208-2213.

Opocher G, Rocco S, Carpene G, Armanini D, Mantero F. Minerva Endocrinol 1995;20: 49-54. (Abstract)

Fehaily MA, Duh QY. Clinical manifestation of aldosteronoma. Surg Clin N Am 2004; 84:887-905.

Stern N, Tuck ML. The adrenal cortex and mineralocorticoid hipertension. En: Lavin N, ed. Manual of Endocrinology and Metabolism. 3 ed., Philadelphia: Lippincott Williams & Wilkins, 2002:115-144.

Young WF Jr. Primary aldosteronism - treatment options. Growth Horm IGF Res. 2003; 13 Suppl A: S102-8. (Abstract)

Montori VM, Young WF Jr. Use of plasma aldosterone concentrationto-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am 2002;31:619-32.

Veglio F, Morello F, Rabbia F, Leotta G, Mulatero P. Recent advances in diagnosis and treatment of primary aldosteronism. Minerva Med 2003;94:259-65. (Abstract)

Williams GH, Dluhy RG. Enfermedades de la corteza suprarrenal. En: Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS, ed. Harrison: Principios de Medicina Interna. 7ed., tomo II., Interamericana McGraw Hill, 1989:2139-2163.

Litchfi eld WR, Dluhy RG. Primary aldosteronism. Endocrinol Metab Clin North Am 1995; 24:593-612.

Gordon R. Mineralocorticoid hypertension. Lancet 1994; 344:240 243.

Nadar S, Lip G, Beevers DG. Primary hyperaldosteronism. Ann Clin Biochem 2003;40: 439-452.

Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young Jr WF. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85:2854-2859.

Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002; 15:896-902.

Rayner BL, Opie LH, Myers JE, Trinder YA, Davidson JS. Screening for primary aldosteronism normal ranges for aldosterone and renin in three South African population groups. S Afr Med J 2001; 91;594-

Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21:315-318.

Kumar A, Lall SB, Ammini A, Peshin SS, Karmarkar MG, Talwar KK, Seth SD. Screening of a population of young hypertensives for primary hyperaldosteronism. J Hum Hypertens 1994;8:731-732.

Lim P, Dow E, Brennan G, Jung R, MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000; 14:311-315.

Fardella C, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profi le, and molecular biology. J Clin Endocrinol Metab 200;85:1863-1867.

Schwatz GL. Prevalence of unrecognized primary aldosteronism in essential hypertension. American Journal of Hypertension 2002; 14 part 2:18A.

Schwartz GL, Turner ST. Prevalence of unrecognized primary aldosteronism in essential hypertension. Am J Hypertens 2002; 15:18A (Abstract).

Kreze A, Okalova D, Vanuga P, Putz Z, Kodaj J, Hrnciar J. Occurrence of primary aldosteronism in a group of ambulatory hypertensive patients. Vnitr Lek 1999;45:17-21.

Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. Journal of Human Hypertension 2003;17:349-352.

Ganguly, A. Prevalence of Primary Aldosteronism in Unselected Hypertensive Populations: Screening and Defi nitive Diagnosis. The Journal of Clinical Endocrinology & Metabolism 2001; 86:40004005.

Connell JMC. Is there an epidemic of primary aldosteronismo? Journal of Human Hypertension 2002 16, 151-152.

Padfi eld PL. Primary aldosteronism, a common entity? the myth persists. Journal of Human Hypertension 2002;16:159-162.

White, PC. Disorders of Aldosterone Biosynthesis and Action. N Engl J Med 1994;331: 250-258.

Schenermann J. B., Sayegh S.I. Kidney Physiology. U.S.A.: Lippincott-Raven, 1998.

Rodríguez FJ, López-Vidriero E. Mineralocorticoides, Hiperaldosteronismos, Hipoaldosteronismos. En: Jara A, ed. Endocrinología. Madrid: Médica Panamericana, 2001:243-249.

Beevers G, Lip G, O’Brien E. ABC of hypertension The pathophysiology of hypertension. British Medical Journal 2001; 322:1912-16.

Weber, K. Aldosterone in congestive heart failure. N Engl J Med; 345:1689-97.

Guyton AC, Hall JE. Texbook of medical physiology. 10ed., U.S.A.: W.B. Saunders Company, 2000.

Berne RM, Levy MN. Fisiología. 3 ed., Madrid: Harcourt, 2001.

Valtin H., Schafer J.A. Renal function: Mechanisms preserving fl uid and solute balance in health. 3ed., U.S.A.: Little, Brown and Company, 1995.

Nadar S, Lip G, Beevers DG. Primary hyperaldosteronism. Ann Clin Biochem 2003;40: 439–452.

Onusko E. Diagnosing secondary hypertension. Am Fam Physician 2003; 67: 67-74.

Gill JR, Bartter FC. Overproduction of sodium retaining steroids by the zona glomerulosa is adrenocorticotropin dependent and mediates hypertension in dexametasone suppressible aldosteronism. J Clin Endocrinol Metab 1981; 53: 331-337.

Luft, FC. Mendellian forms of hypertension and mechanisms of disease. Clinical Medicine & Research 2003;1:291-300.

Dluhy RG, Lifton RP. Glucocorticoid remediable aldosteronismo. J Clin Endocrinol Metab 1999;84:4341-44.

Lim PO, Young WF, McDonald T. A review of the medical treatment of primary aldosteronismo. J Hypertens 2001;19:353-361.

Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan D, Sos TA, Atlas SA, et al. Diagnosis and treatment of primary hyperaldosteronism. Ann. Intern. Med. 1994; 121:877–885.

Tanabe A, Naruse M, Naruse K, Hase M, Yoshimoto T, Tanaka M, Seki T, Demura R, Demura H. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other type of secondary hypertension. Hypertension Res 1997; 20:85–

(Abstract)

Nishimura M, Uzu T, Fujii T, Kuroda S, Nakamura S, Inenaga T, Kimura G. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 33:261–266

Rocha, R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann. N. Y. Acad. Sci 2002; 970, 89–100. (Abstract)

Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, Pessina A. Remodeling of the left ventricle in primary aldosteronism due to Conn´s adenoma. Circulation 1997; 95:1471-1478.

Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002;40:23–27.

McMahon GT, Dluhy RG. Glucocorticoid-remediable aldosteronism. Cardiol. Rev 2004; 12:44–48.

Struthers AD. Aldosterone-induced vasculopathy. Mol. Cell. Endocrinol 2004;217:239–241.

Young Jr WF. Primary aldosteronism: update on diagnosis and treatment. Endocrinologist 1997;7:213-221.

Gennari FJ. Hypokalemia. N Engl J Med 1998; 339:351-58.

Cotran RS, Kumar V, Collins T. Patología structural y functional. 6ed., Mexico: McGraw-Hill Interamericana, 2000.

Ulick Stanley, Blumenfeld JD, Atlas SA, Wang JZ, Vaughan ED. The unique steroidogenesis of th aldosteronoma in the differential diagnosis of primary aldosteronismo. J Clin Endocrin Metab 1993;76:873-878.

Stowasser M, Huggard PR, Rossetti TR, Bachmann AW, Gordon RD. Biochemical evidence of aldosterona overproduction and abnormal regulation in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrin Metab 1999;84: 4031-4036

Hiramatsu K, Yamada T, Yukimura Y, et al. A screening test to identify aldosterona producing adenoma by measuring plasma renin activity:

results in hypertensive patients. Arch Intern Med 1981;141:1589–93.

Montori VM, Young Jr WF 2002 Use of plasma aldosterone concentrationto- plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am 31:619– 632, xi 15

Bravo EL. Primary aldosteronism. Issues in diagnosis and management. Endocrinol Metab Clin North Am 1994; 23:271–283.

Grim CE. Evolution of diagnostic criteria for primary aldosteronism: why is it more common in “drug-resistant” hypertension today? Curr Hypertens Rep 2004; 6: 485-92. (Abstract)

Mulatero, P. et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from fi ve continents. J. Clin. Endocrinol. Metab. 2004; 89:1045–1050.

Mulatero P, Dluhy RG, Giacchetti G, Boscaro M, Veglio F, Stewart PM. Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends in Endocrinology and Metabolism 2005; 16:1114-1119.

Gordon RD. Primary aldosteronism. J Endocrinol Invest 1995; 18:495–511.

Buhler FR, Laragh JH, Baer L, Vaughan ED, Brunner HR. Propanol inhibition of rennin secretion: a specifi c approach to diagnosis and treatment of rennin-dependent hypertensive diseases. N Engl J Med. 1972; 287: 1209-1214.

Gordon MS, Williams GH, Hollenberg NK. Renal and adrenal responsiveness to angiotensin II: infl uence of β-adrenergic blockade. Endocr Res. 1992;18: 115-131.

Tiu SC, Choi CH, Shek CC, Ng YW, Chan FK, Ng CM, Kong AP. The Use of Aldosterone-Renin Ratio as a Diagnostic Test for Primary Hyperaldosteronism and Its Test Characteristics under Different Conditions of Blood Sampling. The Journal of Clinical Endocrinology & Metabolism 2005; 90:72–78.

Brown MJ, Hopper RV. Calcium-channel blockade can mask the diagnosis of Conn´s syndrome. Postgrad Med J. 1999;75:235-236.

Mulatero, P. et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002;40:897-902.

Young WF Jr. Primary aldosteronism: a common and curable form of hypertension. Cardiol Rev. 1999;7:207-214.

Oliveros-Palacios MC, Godoy-Godoy N, Colina-Chourio JA. Effects of doxazosin on blood pressure, rennin-angiotensin-aldosterone and urinary kallikrein. Am J Cardiol. 1991;67:157-161.

Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone renin ratio. Am J Kidney Dis. 2001;37:699-705.

Lei Xu, Viering E, Davidson RC, Toivola B: The diagnosis of primary hyperaldosteronism (PHA) using plasma aldosterone-to-renin activity ratio. Am J Clin Pathol 1994;102:257A. (Abstract)

Schawartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 2005; 51:386-94.

Tanabe A, Naruse M, Takagi S, Imaki T, Takano K. Variability in the Renin/Aldosterone Profi le under Random and Standardized Sampling Conditions in Primary Aldosteronism. J Clin Endocrinol Metab 88:2489–2494.

Francois P, Jeunemaitre X. Would wider screening for primary aldosteronism give any health benefi ts? European Journal of Endocrinology 2004; 151:305–308.

Stowasser M, Gordon RD, Rutherford JC, Nikwan NZ, Daunt N, Slater GJ. Diagnosis and management of primary aldosteronism. JRAAA 2001;2:156-169.

Magill SB, Raff H, Shaker JL, Brickner RC, Knechtges TE, Kehoe ME, Findling JW. Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronismo. J Clin Endocrinol Metab 2001;86:1066-1071.

White EA, Schambelan M, Rost CR, Biglieri EG, Moss AA, Korobkin M. Use of computed tomography in distinguishing the cause of primary aldosterism. N Engl J Med 1980; 303;1503-07.

Mulatero P, Morello F, Veglio F. Genetics of primary aldosteronism. J Hyperten 2004; 22: 663-670.

Jackson EK. Diuretics. En: Hardman JG, Limbird LE, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill;2001:757-787.

Flórez J, Armijo JA. Fármacos diuréticos. En: Flórez J, editor. Farmacología humana. 3 ed. Barcelona: Masson; 1997:815-829.

Mosby’s Drug Consult. www.mdconsult.com. Sitio accesado 15 de noviembre del 2005.

Nadler JL, Hsueh W, Horton R. Therapeutic effect of calcium channel blockade in primary aldosteronism. J Clin Endocrin Metab 1985;60:896-899.

Carpene G, Rocco S, Opacher G, Mantero F. Acute and chronic effect of nifedipine in primary aldosteronism. Clin Exp Hypertens 1989;11:1269-1272. (Abstract)

Stokes GS. Monaghan JC, Ryan M, Woodward M. Effi cacy of an angiotensin II receptor antagonist in managing hyperaldosteronism. J Hypertens 2001;19:1161-65.

Smith DC, Weber CJ, Amerson JR. Laparoscopic Adrenalectomy: New Gold Standard. World J. Surg. 1999;23:389–396.

Shen WT, Lim RC, Siperstein AE, et al. Laparoscopic vs open adrenalectomy for the treatment of primary hyperaldosteronism. Arch Surg 1999;134:628–32.

Chavez J, Pasieka JL. Adrenal lesions assessed in the era of laparoscopic adrenalectomy: a modern day series. The American Journal of Surgery 2005;189: 581–586.

Plouin PF, Amar L, Chatellier G. Trends in the prevalence of primary aldosteronism, aldosterone producing adenomas, and surgically correctable aldosterone dependent hypertension. Nephrology, Dialysis, Transplantation 2004;19:774-777.

Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-223.

Descargas

Publicado

2007-01-01

Cómo citar

Gómez Hernández, K., & Chen-Ku, C. H. (2007). Hiperaldosteronismo primario, una nueva perspectiva. Acta Médica Costarricense, 49(1), 13–20. https://doi.org/10.51481/amc.v49i1.287